In the Nakatani et al. study, there was no significant difference in the gastric, duodenal, and small intestine transit time after GLP-1 RA use compared to before starting GLP-1 RAs in diabetic patients with neuropathy; however, the gastrointestinal transit time was significantly increased after GLP-1 RA administration compared to before starting the GLP1 analogue liraglutide in diabetic patients without neuropathy [33]. The gene discussed is GLP1R; the disease is neuropathy.